LumiThera, Inc.
Valeda is FDA Authorized in the US, CE Marked in the EU, and available in select countries in Latin America.
Valeda is FDA Authorized in the US, CE Marked in the EU, and available in select countries in Latin America.
LumiThera, Inc. is a United States-based startup focused on developing therapies for degenerative eye diseases using Photobiomodulation. The company's flagship product, the Valeda® Light Delivery System, utilizes multiwavelength photobiomodulation to treat dry age-related macular degeneration (AMD). While CE Marked in the EU and available in select Latin American countries, it is not cleared by the Food & Drug Administration (FDA) in the USA. Additionally, their AdaptDx Pro® dark adaptation functional testing technology allows early detection and monitoring of AMD, and the Diopsys® ERG and VEP systems aid in analyzing visual and neuro-visual disorders. The last recorded investment for LumiThera was a significant $2.43M Venture Round investment on May 21, 2024. As the company continues to advance its innovative light-based solutions in the healthcare and manufacturing industries, it presents an intriguing opportunity for venture capital firms seeking to support groundbreaking technologies addressing critical medical needs.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $2.43M | - | 21 May 2024 | |
| Debt Financing | $5.50M | 3 |
|
10 Mar 2022 |
| Series C | $14.00M | 4 |
|
08 Jul 2020 |
| Series B | $5.50M | 3 |
|
31 Oct 2017 |
| Venture Round | Unknown | 1 |
|
01 Dec 2016 |
We care about your data, and we'd love to use cookies make your experience better.
